Whitehawk Therapeutics Inc (WHWK)
Automate Your Wheel Strategy on WHWK
With Tiblio's Option Bot, you can configure your own wheel strategy including WHWK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol WHWK
- Rev/Share 0.6961
- Book/Share 5.5572
- PB 0.3419
- Debt/Equity 0.0
- CurrentRatio 18.9518
- ROIC -0.2849
- MktCap 89507670.0
- FreeCF/Share -1.334
- PFCF -1.6816
- PE 2.7453
- Debt/Assets 0.0
- DivYield 0
- ROE 0.2618
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
MORRISTOWN, N.J. , May 21, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA, on May 28, 2025, at 2:30 PM ET.
Read More
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
MORRISTOWN, N.J. , March 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced the successful closing of the divestiture of Aadi Subsidiary, Inc. ("Aadi Sub") to Kaken Pharmaceuticals ("Kaken") for a cash payment of $100 million plus certain customary adjustments, completing the strategic transformation first announced in December 2024.
Read More
About Whitehawk Therapeutics Inc (WHWK)
- IPO Date 2017-08-01
- Website https://ir.whitehawktx.com
- Industry Biotechnology
- CEO David J. Lennon
- Employees 40